Wire · regulatory
B. Braun Medical Lobbies FDA and Drug Quality Security Act
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
B. Braun Medical disclosed $116,500 in lobbying to the FDA and on the Drug Quality and Security Act in Q3 2026, focusing on drug shortages, generic pharmaceuticals, medical device regulation, and pharmacy compounding issues under Sections 503A and 503B.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You face tighter FDA scrutiny and regulatory shifts on drug quality and compounding pharmacy rules, with drug shortages creating exceptions but also risks for compliance. This changes how you manage product lines and market access in generic pharmaceuticals and medical devices.
◆ Coverage
1 source · 12 Oct 2026
◆ Related on Wire
◆ Topics